key: cord-1001945-bq7krt35 authors: Vinci, R.; Pedicino, D.; Andreotti, F.; Russo, G.; D'Aiello, A.; De Cristofaro, R.; Crea, F.; Liuzzo, G. title: From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19 date: 2020-11-10 journal: Int J Cardiol DOI: 10.1016/j.ijcard.2020.11.016 sha: d9a03b92093982c33f3dcd00b92d67f5a666fb32 doc_id: 1001945 cord_uid: bq7krt35 We concisely review the clinical, autopsy, experimental and molecular data of 2019 coronavirus disease (COVID-19). Angiotensin-converting enzyme 2 disruption and thromboinflammatory microangiopathy emerge as distinctive features. Briefly, entry of the virus into microvessels can profoundly disrupt the local renin-angiotensin system, cause endothelial injury, activate the complement cascade and induce powerful thromboinflammatory reactions, involving, in particular, von Willebrand factor, that, if widespread, may lead to microvascular plugging, ischemia and, ultimately, organ failure. We believe the current COVID-19 data consolidate a widely unrecognised paradigm of potentially fatal thromboinflammatory microvascular disease. viral infection of capillary endothelial cells, endotheliitis and inflammatory-cell death [2] [3] [4] [5] ; additionally, widespread microthrombi, leukocyte plugs, perivascular inflammation, and intense microvascular complement deposition have been consistently reported [2] [3] [4] [5] . COVID-19 patients hospitalised for chest symptoms and associated focal or diffuse ST-segment elevation or myocardial dysfunction show frequent lack of obstructive epicardial artery disease [6, 7] , pointing to microvascular impairment as a likely underlying cause of acute myocardial damage. In turn, raised cardiac troponin levels (indicating myocardial injury) are positively related to both inflammatory and coagulation markers and to mortality [8] [9] . The specific cluster of plasma cytokines of COVID-19 patients admitted to intensive care units (ICU), compared to non-ICU COVID-19 patients, suggests a cytokine vicious spiral (cytokine storm) negatively affecting outcomes [9] (for complete list of cytokines see Table 1 ). Specifically, interleukin (IL)-6 levels are strongly related to prognosis, as in acute coronary syndromes and in classical inflammatory immune diseases such as rheumatoid arthritis [10] . Severe COVID-19 patients also develop systemic hypercoagulability, as indicated by raised plasma levels of fibrinogen, D-dimer, VWF and factor VIII [8, 9, [11] [12] [13] [14] . The systemic proinflammatory response, that in extreme cases may lead to disseminated coagulopathy, is reminiscent of the cytokine plethora and kinetics of septic conditions [15] , pointing to viral SARS-CoV-2 sepsis in critical forms of COVID-19 [16, 17] . Inflammatory activation, lymphopenia and thrombocytopenia reported in severe COVID-19 resemble another potentially fatal syndrome triggered by viral infections, characterised by leukopenia, macrophage hyperactivity, multiorgan failure and hyperinflammation, i.e., secondary haemophagocytic lymphohistiocytosis [18] . The blood stigmata of severe COVID-19 are compatible with lymphopenia secondary to cytokine-induced complement activation and with thrombocytopenia secondary to VWF hypersecretion and microvascular thrombosis [2, 8, 9, 18, 19] . COVID-19 lymphopenia is characterised by reduced circulating CD4+ and CD8+ T-lymphocytes and is related to both cytokine levels and adverse prognosis [20] . It has been hypothesised that J o u r n a l P r e -p r o o f Journal Pre-proof SARS-CoV-2 may directly infect lymphocytes, particularly T cells, promoting their death, with consequent lymphopenia and impaired antiviral responses [16] . The recent emerging benefits of dexamethasone and anticoagulant treatments, even in the absence of large artery occlusions, corroborate the pivotal role of inflammation and thrombosis in SARS-CoV-2 infection [12] [13] [14] [21] [22] [23] . SARS-CoV-2 uses its spike 1 glycoprotein to bind to the human membrane receptor ACE2 [24, 25] . Organs expressing ACE2including lung, intestines, kidney, myocardiocytes and endothelium -are potential SARS-CoV-2 targets [5, 24, 26] . Both SARS-CoV and SARS-CoV-2 bind to ACE2, but SARS-CoV-2 has a particularly snug fit and is 10-20 times more likely to bind ACE2 than SARS-CoV [25] . Fusion of SARS-CoV-2 to the host cell membrane is further facilitated by human furin or other membrane enzymes such as TMPRSS2 [25] . Viral entry causes internalisation and functional ACE2 disruption [24, 25] . Under physiological conditions, ACE2 cleaves angiotensin(Ang)II to generate Ang (1-7) and, less efficiently, Ang I to generate Ang(1-9); the latter can generate further Ang(1-7) via neutral endopeptidase (neprilysin) or ACE [27] . In addition to anti-inflammatory and anti-oxidant properties (see below), Ang(1-7) boasts vasorelaxing and antithrombotic ones through the release of bioactive nitric oxide, tissue-type plasminogen activator and bradykinin ( Figure 1 ) [28] . These effects are mediated by Ang(1-7)'s binding to the endothelial membrane G-protein-coupled Mas receptor (MAS-R) [27] . Thus, SARS-CoV-2 binding to ACE2 not only allows the virus to invade and destroy cells [24, 25] , but also disrupts the vasorelaxing and antithrombotic properties of ACE2, while enhancing the harmful ones of Ang II, a potent direct vasoconstrictor and bradykinin inhibitor [28] . Ang II additionally triggers endothelial secretion of VWF from Weibel Palade bodies [29] and the vascular expression of the fibrinolysis inhibitor, plasminogen activator inhibitor-1 (PAI-1) [30] (Figure 1 ). In contrast to ACE2, ACE is a membrane receptor that J o u r n a l P r e -p r o o f Journal Pre-proof converts Ang I to Ang II. ACE-inhibitors (ACEI), as well as angiotensin receptor blockers (ARB), by reducing Ang II"s negative effects, are likely to act favourably in COVID-19 patients, as suggested by recent reports [31] . The alveolar-capillary membrane and pulmonary microvasculature are particularly rich in ACE2 [5, 24] ; they constitute a major portal for viral blood dissemination [16] and are structurally poised to suffer the full-blown thromboinflammatory effects of ACE2 disruption induced by SARS-CoV-2. Ang (1-7), in addition to its vasorelaxing and antithrombotic effects, has major anti-inflammatory properties. This is supported by murine models of rheumatoid arthritis in which AVE 0991, an Ang(1-7) mimetic and agonist of the MAS-R [32, 33] , decreases the rolling, adhesion and influx of leukocytes into synovial microvascular endothelium through chemokine ligand blockade [34] . Thus, microvascular SARS-CoV-2 induced internalisation and functional disruption of ACE2 [24, 25] likely exerts powerful proinflammatory effects. Endothelium represents a rich source of ACE2 receptors [5, 24] . Widespread microangiopathy with complement deposits in severe COVID-19 cases points toward systemic microvascular endothelial J o u r n a l P r e -p r o o f Journal Pre-proof dysfunction [2] [3] [4] [5] 14] . Importantly, thrombotic microangiopathy is reported as a distinctive feature of COVID-19 respiratory insufficiency, being absent in influenza-related respiratory failure [5] . Activated endothelium, as well as host-defense mechanisms against viral antigens, can trigger complement activation (a crucial innate immune element) by classical, alternative or lectin pathways, through C3, C5, and generation of the C5b-9 membrane attack complex (MAC); the latter destroys target cells [2, 19] ; significant microvascular C5b-9 deposits have been documented in COVID-19 patients [2] . Complement activation, while attempting to neutralise infection through cell lysis, also has proinflammatory, chemotactic, anaphylotoxic and prothrombotic repercussions and can induce T-lymphopenia ( Figure 1) [2, 19, 37] . A systemic endothelial microangiopathy in SARS-CoV-2 infection is further supported by elevated circulating inflammatory and prothrombotic factors, particularly VWF, an established marker of endothelial dysfunction [12] [13] [14] ; patients with classical thrombotic microangiopathy accumulate prothrombotic high molecular weight VWF multimers [19, 37] ; in COVID-19 patients requiring invasive mechanical ventilation, VWF levels 3-to-4 fold higher than the upper normal limit have been reported [38] ; interestingly, nonhaemostatic functions of VWF include complement activation [37] ; in turn, complement hyperactivation, which has been documented in moderate and severe COVID-19 [39] , can lead to thrombotic microangiopathy [19] . The shift in RAS balance toward Ang II, likely induced by the SARS-CoV-2 interaction with vascular ACE2 [5, 24, 25] , may be a further trigger for VWF release [29] . High plasma levels of VWF promote not only platelet rolling, adhesion and aggregation, but also leukocyte extravasation and further C5a and C5b-9 generation [37] ; the latter may cause MAC-cell lysis with secondary tissue factor exposure, thrombin/fibrin formation, further platelet adhesion/aggregation, and microvascular thrombosis; PAI-1, from activated endothelium and aggregated platelets, likely contributes to consolidate the fibrin network surrounding aggregated blood elements [30] (Figure 1) . The high fatality rate of COVID-19 and the aforementioned heterogeneity of basic science and clinical reports have led to the planning of numerous drug trials, including antiviral, antithrombotic and anti-inflammatory agents [40] . To date, only the anti-inflammatory steroid, dexamethasone, has been shown to improve survival for those requiring respiratory support [23] and the antiviral agent, remdesivir, to reduce time to recovery [41] . Complement inhibition may specifically interfere with the vicious spiral of COVID-19 microvascular impairment [42, 43] . ACEI, as well as ARB, are key drugs in cardiovascular diseases and in the management of hypertension [44] [45] [46] [47] . Despite early unfavourable publicity [48] , the use of ARB/ACEI in COVID-19 has been associated with promising outcomes [31] and recombinant human ACE2 protein is under evaluation as a potential supportive treatment [49] . Anticoagulant drugs are under investigation in randomised trials [50] . Emerging distinctive features of severe SARS-CoV-2 infection include powerful ACE2 disruption and widespread thromboinflammatory microangiopathy. Further insights into COVID-19 pathophysiology and data from ongoing clinical trials will be crucial to discover targeted effective treatments. Focusing on the similarities between human SARS-CoV-2 infection and other diseases [18, 19, 24, 37, 51] , and addressing the consequences of COVID-19, especially among patients prone to chronic inflammatory conditions such as cardiovascular diseases [52, 53] , will contribute to overall progress and to preparedness against a virus that is expected to hang around for some years [24] . Independently from SARS-CoV-2, we believe current COVID-19 data consolidate a widely unrecognised paradigm of potentially fatal thromboinflammatory microvascular disorders. Right: endothelial cell lysis, TF expression, release of VWF and PAI-1 from activated endothelium (green circles) contribute to leukocyte influx and to microthrombosis through platelet adhesion, aggregation and coagulation. Thrombocytopenia may signal widespread thrombosis. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction Endothelial cell infection and endotheliitis in COVID-19 Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 ST-Segment Elevation in Patients with Covid-19 -A Case Series ST-Elevation Myocardial Infarction in Patients with COVID-19: Clinical and Angiographic Outcomes Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events Acute pulmonary embolism in COVID-19 disease: Preliminary report on seven patients Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 Cytokine storm and sepsis disease pathogenesis SARS-CoV-2 and viral sepsis: observations and hypotheses Coronavirus Disease COVID-19: consider cytokine storm syndromes and immunosuppression Diagnostic Testing for Differential Diagnosis in Thrombotic Microangiopathies Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19 Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 Profile of a killer: the complex biology powering the coronavirus pandemic Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system Angiotensin-(1-7) augments bradykinininduced vasodilation by competing with ACE and releasing nitric oxide Angiotensin II directly triggers endothelial exocytosis via protein kinase C-dependent protein kinase D2 activation Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas Vieira AT Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis Role of von Willebrand Factor and ADAMTS-13 in the Pathogenesis of Thrombi in SARS-CoV-2 Infection: Time to Rethink Complement activation in patients with COVID-19: A novel therapeutic target COVID-19 trials in Italy: A call for simplicity, top standards and global pooling Remdesivir for the Treatment of Covid-19 -Preliminary Report Targeting complement in severe coronavirus disease 2019 to address microthrombosis Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection Angiotensin converting enzyme inhibition in patients with congestive heart failure Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension SARS-CoV2: should inhibitors of the reninangiotensin system be withdrawn in patients with COVID-19? Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19 COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in J o u r n a l P r e -p r o o f acute myocardial infarction Infections, immunity and atherosclerosis: pathogenic mechanisms and unsolved questions Coronary microvascular dysfunction: an update